- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01339988
Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
April 20, 2011 updated by: Tel-Aviv Sourasky Medical Center
Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants
Long-term follow-up studies have demonstrated significant late toxicities of total body irradiation (TBI), which are most marked in children radiated at a young age.
Growth failure, decline in cognitive function, and endocrine abnormalities have all been described.
Good outcomes can be achieved with alkylating agents only as a preparative regimen.
This plan will use a combination of busulfan and cyclophosphamide (Bu/Cy) with or without antithymocyte globulin (ATG) to reduce the late toxicities of therapy that includes TBI.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
10
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 21 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Suitable cord blood from matched unrelated or related donor.
- Cardiac (Echo/EKG): shortening fraction ≥ 27%
- Electrolytes within normal CCHMC limits.
- Pulmonary function tests: DLCO ≥ 50%
- Renal: creatinine clearance/GFR ≥ 60 ml/minute/1.73m2
- Lumbar puncture: no leukemic infiltrate.
- CBC: ANC ≥ 1000ml and unsupported platelet count of ≥ 50,000/ml
- Documented HSV and CMV titers, Hepatitis B surface antigen, Hepatitis C by serology, HIV by serology: all negative.
- Hepatic transaminases < 2.5x normal; Total bilirubin < 2 mg/dl Patients who do not meet above organ function criteria (liver, cardiac, renal), due to the presence of a tumor compromising these organs, may have exception made for these criteria and remain eligible for treatment plan after consultation with Program Director of Blood and Marrow Transplant
Exclusion Criteria:
- Patients with neoplastic or non-neoplastic disease of any major organ system that would compromise their ability to withstand the pre-transplant conditioning regimen.
- Patients with uncontrolled (culture or biopsy positive) infections requiring intravenous antivirals, antibiotics, or antifungals. Patients on prolonged antifungal therapy with a history of fungal infection should be considered for a non-myeloablative protocol.
- Patients who are pregnant or lactating. Patients of childbearing potential must practice an effective method of birth control while participating on this treatment plan.
- HIV seropositive patients
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Busulfan/Cyclophosphamide
|
Conditioning regimen: Cyclophosphamide 50mg/kg/day for 4 days + Busulfan 0.8-1.0mg/kg/day for 4 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival
Time Frame: Five years
|
Five years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease free survival
Time Frame: Five years
|
Five years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2011
Primary Completion (Anticipated)
June 1, 2014
Study Completion (Anticipated)
June 1, 2019
Study Registration Dates
First Submitted
April 20, 2011
First Submitted That Met QC Criteria
April 20, 2011
First Posted (Estimate)
April 21, 2011
Study Record Updates
Last Update Posted (Estimate)
April 21, 2011
Last Update Submitted That Met QC Criteria
April 20, 2011
Last Verified
April 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Bone Marrow Diseases
- Hematologic Diseases
- Myelodysplastic-Myeloproliferative Diseases
- Leukemia, Myeloid
- Myelodysplastic Syndromes
- Leukemia
- Leukemia, Myelomonocytic, Juvenile
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Busulfan
Other Study ID Numbers
- TASMC-11-MB-442-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Juvenile Myelomonocytic Leukemia
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedJuvenile Myelomonocytic LeukemiaUnited States, Canada, Australia, New Zealand
-
National Cancer Institute (NCI)CompletedJuvenile Myelomonocytic LeukemiaUnited States
-
Masonic Cancer Center, University of MinnesotaCompletedJuvenile Myelomonocytic LeukemiaUnited States
-
Masonic Cancer Center, University of MinnesotaTerminated
-
M.D. Anderson Cancer CenterAmgenTerminated
-
Gustave Roussy, Cancer Campus, Grand ParisRecruitingMyelomonocytic LeukemiaFrance
-
University of UtahCelgeneCompletedChronic Myelomonocytic LeukemiaUnited States
-
Arbeitsgemeinschaft medikamentoese TumortherapieCelgene CorporationUnknownChronic Myelomonocytic LeukemiaAustria
-
Groupe Francophone des MyelodysplasiesJanssen-Cilag Ltd.CompletedChronic Myelomonocytic LeukemiaFrance
-
Columbia UniversityCompletedJuvenile Myelomonocytic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous LeukemiaUnited States
Clinical Trials on Busulfan/Cyclophosphamide
-
University Hospital, Basel, SwitzerlandUniversity Hospital, Geneva; University Hospital, ZürichCompletedMyeloid Leukemia | Precursor Myeloid Neoplasms | Lymphoid NeoplasmsSwitzerland
-
Memorial Sloan Kettering Cancer CenterCompletedSickle Cell Anemia | Genetic DisordersUnited States
-
Emory UniversityCompletedHematologic MalignanciesUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)Completed
-
Northwestern UniversityNational Cancer Institute (NCI)CompletedLeukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
Nanfang Hospital of Southern Medical UniversityXiangya Hospital of Central South University; Guangzhou First People's Hospital and other collaboratorsCompletedAcute Lymphocytic Leukemia | Allogeneic Hematopoietic Stem Cell Transplantation | Busulfan | Total Body IrradiationChina
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI)Completed
-
Vastra Gotaland RegionRecruitingStem Cell Transplantation | Acute Myeloid Leukemia (AML) in RemissionBelgium, Denmark, Finland, Hong Kong, Israel, Lithuania, Netherlands, Norway, Spain, Sweden
-
Nanfang Hospital of Southern Medical UniversityPeking University People's Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen... and other collaboratorsRecruitingAllogeneic Hematopoietic Stem Cell Transplantation | Conditioning | Myeloid TumorsChina
-
Cooperative Study Group A for HematologyCompletedLeukemia | Myelodysplastic SyndromeKorea, Republic of